

E3N Study - The French E3N Prospective Cohort Study

Head :Severi Gianluca, Inserm - Centre de Recherche en Epidémiologie et Santé des Populations (CESP) - Team Exposome and Heredity
Boutron-Ruault Marie-Christine, Inserm - Centre de Recherche en Epidémiologie et Santé des Populations (CESP) - Team Exposome and Heredity

Last update : 12/21/2020 | Version : 8 | ID : 3162

General

Identification

Detailed name The French E3N Prospective Cohort Study

Sign or acronym E3N Study

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL n°327346 V 13, CPP (03/12/2008)

General Aspects

Medical area
Biology
Cancer research
Cardiology
Dermatology, venereology
Disability/handicap
Endocrinology and metabolism
Gastroenterology et hepatology
Geriatrics
Gynecology/ obstetrics
Hematology
Infectious diseases
Neurology
Pneumology
Psychology and psychiatry
Radiology and medical imaging
Rheumatology
Study of allergies
Traumatology

Study in connection with Covid-19 Yes

Health determinants
Genetic
Geography
Lifestyle and behavior
Medicine
Nutrition
Occupation

Pollution
Social and psychosocial factors

Scientific investigator(s) (Contact)

Name of the director	Severi
Surname	Gianluca
Address	Gustave Roussy Institute, Espace Maurice Tubiana, 114 rue Edouard Vaillant, 94805 Villejuif
Phone	+33 (0)1 42 11 41 48
Email	gianluca.severi@inserm.fr
Unit	Inserm - Centre de Recherche en Epidémiologie et Santé des Populations (CESP) - Team Exposome and Heredity
Organization	Inserm, Université Paris-Saclay, Institut Gustave Roussy

Name of the director	Boutron-Ruault
Surname	Marie-Christine
Address	Gustave Roussy Institute, Espace Maurice Tubiana, 114 rue Edouard Vaillant, 94805 Villejuif
Phone	+33 (0)1 42 11 64 66
Unit	Inserm - Centre de Recherche en Epidémiologie et Santé des Populations (CESP) - Team Exposome and Heredity
Organization	Inserm, Université Paris-Saclay, Institut Gustave Roussy

Collaborations

Participation in projects, networks and consortia	Yes
--	-----

Details	European EPIC study (European Prospective Investigation into Cancer and Nutrition)
---------	---

Funding

Funding status

Mixed

Details

Ligue nationale contre le Cancer, Inserm, Gustave Roussy, MGEN, European Union (for the EPIC study) - Additional funding through call for projects

Governance of the database

Sponsor(s) or organisation(s) responsible

Institut National de la Santé et de la Recherche Médicale - Inserm

Organisation status

Public

Sponsor(s) or organisation(s) responsible

Université Paris-Saclay

Organisation status

Public

Sponsor(s) or organisation(s) responsible

Institut Gustave Roussy

Organisation status

Both

Organisation status

Presence of scientific or steering committees

Yes

Additional contact

Main features

Type of database

Type of database

Study databases

Study databases (details)

Cohort study

Database recruitment is carried out by an intermediary

A population file

Database recruitment is carried out as part of an interventional study

No

Additional information regarding sample selection.

In 1990, recruiting via an informative MGEN-INSERM letter sent along with an inclusion questionnaire to all women who are members of the MGEN and born between 1925 and 1950..

Database objective

Main objective Detecting risk factors of cancer and chronic pathologies in women

Inclusion criteria Women born between 1925 and 1950 and affiliated with MGEN (Mutuelle Générale de l'Education nationale)

Population type

Age Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered General population

Pathology

Gender Woman

Geography area National

Detail of the geography area France

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 1990

Date of last collection (YYYY or MM/YYYY) 2020

Size of the database

Size of the database (number of individuals) Greater than 20 000 individuals

Details of the number of individuals 98 995

Data

Database activity Current data collection

Type of data collected
Clinical data
Declarative data
Paraclinical data
Biological data
Administrative data

Clinical data (detail)	Direct physical measures
Details of collected clinical data	Anatomopathological report and / or hospital records to confirm and clarify the reported diseases
Declarative data (detail)	Paper self-questionnaire Internet self-questionnaire Phone interview
Details of collected declarative data	Lifestyle and health information
Paraclinical data (detail)	imaging (mammographies....)
Biological data (detail)	within the framework of case/controls studies: hormone levels, vitamin status, biomarkers
Administrative data (detail)	identifying data
Presence of a biobank	Yes
Contents of biobank	Whole blood Serum Plasma Fluids (saliva, urine, amniotic fluid, ?) Tissues DNA
Details of biobank content	Blood from a sample of 25,000 women taken between 1994 and 1998: erythrocytes, buffy coat (lymphocytes), serum, plasma. Saliva from a sample of 47,000 other women collected between 2009 and 2011. Tumor Bank : breast cancers' tumoral tissues
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception
Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption
Procedures	
Data collection method	Self-questionnaire at inclusion and then every three years during follow-up: Collection of data on the state of health, lifestyle, plus specific questionnaires under the responsibility of a researcher or for another project (on sub-samples).- Clinical

examination at inclusion for a sub-sample of 25,000 women in the cohort: pulse, blood pressure, weight, height. Data collected between 1994 and 1998 when blood samples were taken.-
Questionnaire with the general practitioners in the case of a pathology declared by the woman: confirmation and anatomopathological report for more than 80 % of cancers.

Classifications used ICD 9 and ICD 10

Participant monitoring Yes

Monitoring procedures
Monitoring by contact with the participant (mail, e-mail, telephone etc.)
Monitoring by contact with the referring doctor
Monitoring by crossing with a medical-administrative database
Monitoring by crossing with a morbidity register

Details on monitoring of participants
The duration of follow-up for the women participating in the study is undetermined, as the objective is to follow them as long as possible, until death.

Followed pathology C00-C97 - Malignant neoplasms

E10-E14 - Diabetes mellitus

G20 - Parkinson disease

N80 - Endometriosis

J45 - Asthma

I10-I15 - Hypertensive diseases

K50 - Crohn disease [regional enteritis]

K58 - Irritable bowel syndrome

F32 - Depressive episode

Links to administrative sources Yes

Linked administrative sources (detail) CépiDC, health insurance care reimbursement data (SNIIR-AM), MGEN

Promotion and access

Promotion

Link to the document	http://www.hal.inserm.fr/E3N
Description	List of publications in HAL
Link to the document	http://www.ncbi.nlm.nih.gov/pubmed/?term=E3N-EPIC+OR+%28E3N+AND+%28cohort+OR+escape%29%29+NOT+23110838[uid]
Description	List of publications in Pubmed
Link to the document	http://epic.iarc.fr/
Link to the document	https://www.e3n.fr/les-articles-scientifiques
Description	List of the principal publications of the team
Access	
Dedicated website	https://www.e3n.fr
Presence of document that lists variables and coding procedures	Yes
Terms of data access (charter for data provision, format of data, availability delay)	Data access methods for outside teams: authorization request to the scientific committee of the E3N study
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only